Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference
31 October 2007 - 11:00PM
PR Newswire (US)
WESTMINSTER, Colo., Oct. 31 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer, today announced that Paul
L. Berns, President and CEO, will present a corporate overview at
the 2007 Acumen BioFin Rodman & Renshaw Conference in New York.
The Company's presentation will take place at 8:50 a.m. (Eastern)
on Tuesday, November 6, 2007. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
Allos website home page and investor relations section. The webcast
will be available for replay on Allos' website through November 20,
2007. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in
a pivotal Phase 2 (PROPEL) trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The PROPEL trial is being
conducted under an agreement reached with the U.S. Food and Drug
Administration under its special protocol assessment, or SPA
process. The Company is also investigating PDX in patients with
non-small cell lung cancer and a range of other lymphoma sub-types.
The Company's other product candidate is RH1, a targeted
chemotherapeutic agent, for which the Company expects to initiate a
Phase 1 trial in patients with advanced solid tumors in the fourth
quarter of 2007. For additional information, please visit the
Company's website at http://www.allos.com/. Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2006 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice
President, Investor Relations of Allos Therapeutics, Inc.,
+1-720-540-5367, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics (MM) News Articles